Randomized Controlled Study on Personalized Acupoint Acupuncture Combined with Accelerated Deep Transcranial Magnetic Stimulation (adTMS) for Mild Cognitive Impairment (MCI)

注册号:

Registration number:

ITMCTR2025000652

最近更新日期:

Date of Last Refreshed on:

2025-04-06

注册时间:

Date of Registration:

2025-04-06

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

个性化穴位针灸联合加速深部经颅磁刺激(adTMS)治疗轻度认知障碍(MCI)的随机对照研究

Public title:

Randomized Controlled Study on Personalized Acupoint Acupuncture Combined with Accelerated Deep Transcranial Magnetic Stimulation (adTMS) for Mild Cognitive Impairment (MCI)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

个性化穴位针灸联合加速深部经颅磁刺激(adTMS)治疗轻度认知障碍(MCI)的随机对照研究

Scientific title:

Randomized Controlled Study on Personalized Acupoint Acupuncture Combined with Accelerated Deep Transcranial Magnetic Stimulation (adTMS) for Mild Cognitive Impairment (MCI)

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

夏静

研究负责人:

夏静

Applicant:

Xia Jing

Study leader:

Xia Jing

申请注册联系人电话:

Applicant telephone:

+86 158 5130 4283

研究负责人电话:

Study leader's telephone:

+86 158 5130 4283

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xj109664986@126.com

研究负责人电子邮件:

Study leader's E-mail:

xj109664986@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

江苏省南通市崇川区新华路298号

研究负责人通讯地址:

江苏省南通市崇川区新华路298号

Applicant address:

No. 298 Xinhua Road, Chongchuan District, Nantong City, Jiangsu Province

Study leader's address:

No. 298 Xinhua Road, Chongchuan District, Nantong City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南通市第二人民医院

Applicant's institution:

The second people's hospital of Nantong

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024-014

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

南通市第二人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Nantong Second People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/7/5 0:00:00

伦理委员会联系人:

于旭旭

Contact Name of the ethic committee:

Yu Xuxu

伦理委员会联系地址:

江苏省南通市崇川区新华路298号

Contact Address of the ethic committee:

No. 298 Xinhua Road, Chongchuan District, Nantong City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 513 8555 4306

伦理委员会联系人邮箱:

Contact email of the ethic committee:

nt2y@163.com

研究实施负责(组长)单位:

南通市第二人民医院

Primary sponsor:

The second people's hospital of Nantong

研究实施负责(组长)单位地址:

江苏省南通市崇川区新华路298号

Primary sponsor's address:

No. 298 Xinhua Road, Chongchuan District, Nantong City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

南通市

Country:

China

Province:

Jiangsu Province

City:

Nantong

单位(医院):

南通市第二人民医院

具体地址:

江苏省南通市崇川区新华路298号

Institution
hospital:

The second people's hospital of Nantong

Address:

No. 298 Xinhua Road, Chongchuan District, Nantong City, Jiangsu Province

经费或物资来源:

南通市卫生健康委员会青年课题(QN2024032),南通市科技局社会民生科技计划项目(MSZ2024088)

Source(s) of funding:

Nantong Municipal Health Commission Youth Research Project (QN2024032); Nantong Municipal Science and Technology Bureau Social Livelihood Science and Technology Program Project (MSZ2024088)

研究疾病:

轻度认知障碍(MCI)

研究疾病代码:

Target disease:

Mild Cognitive Impairment (MCI)

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本研究旨在验证个性化穴位针灸联合加速深部经颅磁刺激(adTMS)对轻度认知障碍(MCI)患者的认知功能改善效果,结合中医辨证分型与现代神经影像学技术(fMRI),探索中西医协同干预的生物学机制。主要终点为治疗12周后MoCA(蒙特利尔认知评估量表)评分变化,次要终点包括神经电生理(P300潜伏期)、脑代谢(MRS-NAA/Cr比值)及日常生活能力(改良Barthel指数)的改善。

Objectives of Study:

This study aims to validate the efficacy of personalized acupoint acupuncture combined with adTMS in improving cognitive function in MCI patients. By integrating Traditional Chinese Medicine (TCM) syndrome differentiation with modern neuroimaging (fMRI), the biological mechanisms underlying the synergistic effects of this integrated intervention will be explored. The primary endpoint is the change in MoCA (Montreal Cognitive Assessment) scores after 12 weeks of treatment. Secondary endpoints include improvements in neuroelectrophysiology (P300 latency), brain metabolism (MRS-NAA/Cr ratio), and daily living abilities (modified Barthel Index).

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

[1] 年龄50-80岁,符合Petersen MCI诊断标准(MoCA评分18-25分,MMSE≥24分); [2] MRI排除结构性病变(脑梗死、肿瘤、脑出血后遗症); [3] 无癫痫病史或颅内金属植入物; [4] 自愿签署知情同意书,能够配合完成中医证候评估及随访。

Inclusion criteria

[1] Age 50–80 years, meeting Petersen’s MCI diagnostic criteria (MoCA score 18–25, MMSE ≥24); [2] MRI exclusion of structural lesions (cerebral infarction, tumor, post-hemorrhagic sequelae); [3] No history of epilepsy or intracranial metal implants; [4] Willing to sign informed consent and comply with TCM syndrome assessments and follow-up.

排除标准:

[1] 严重抑郁(HAMD≥17分)或其他精神疾病(如精神分裂症); [2] 近期(<4周)使用胆碱酯酶抑制剂、抗抑郁药物或免疫调节剂; [3] 合并严重心、肝、肾功能不全(Cr≥2.0 mg/dL,ALT≥3倍正常值上限); [4] 无法耐受针灸或TMS治疗(如晕针史、皮肤过敏)。

Exclusion criteria:

[1] Severe depression (HAMD ≥17) or other psychiatric disorders (e.g., schizophrenia); [2] Recent use (<4 weeks) of cholinesterase inhibitors, antidepressants, or immunomodulators; [3] Severe cardiac, hepatic, or renal dysfunction (Cr ≥2.0 mg/dL, ALT ≥3×ULN); [4] Intolerance to acupuncture or TMS (e.g., needle phobia, skin allergies).

研究实施时间:

Study execute time:

From 2024-09-01

To      2025-05-31

征募观察对象时间:

Recruiting time:

From 2024-09-10

To      2025-05-31

干预措施:

Interventions:

组别:

联合组

样本量:

40

Group:

Combination

Sample size:

干预措施:

个性化针灸 + adTMS

干预措施代码:

Intervention:

Acupuncture and adTMS

Intervention code:

组别:

安慰剂组

样本量:

40

Group:

Placebo group

Sample size:

干预措施:

假TMS(伪线圈) + 假针灸

干预措施代码:

Intervention:

Sham TMS + sham acupuncture

Intervention code:

组别:

单刺激组

样本量:

40

Group:

Stimulation group

Sample size:

干预措施:

adTMS + 假针灸

干预措施代码:

Intervention:

adTMS + sham acupuncture

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏省

市(区县):

南通市

Country:

China

Province:

Jiangsu Province

City:

Nantong City

单位(医院):

南通市第二人民医院

单位级别:

三级

Institution/hospital:

The second people's hospital of Nantong

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

MRS检测前扣带回NAA/Cr比值

指标类型:

次要指标

Outcome:

MRS-NAA/Cr ratio

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

P300潜伏期

指标类型:

次要指标

Outcome:

P300 latency

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗12周时MoCA评分变化

指标类型:

主要指标

Outcome:

MoCA score change at 12 weeks

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良Barthel指数(MBI)

指标类型:

次要指标

Outcome:

modified Barthel Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 50
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究采用计算机生成的随机数字表进行简单随机化。由主要研究者使用统计软件生成随机序列,将符合入选/排除标准的受试者按1:1:1比例分配至三组(联合组、单刺激组、安慰剂组)。随机序列生成后,研究者依据序列顺序对受试者进行分组,确保分配过程透明且不可预测。

Randomization Procedure (please state who generates the random number sequence and by what method):

The study utilized a computer-generated random number table for simple randomization. The principal investigator generated the random sequence using statistical software, assigning eligible participants to three groups (Combination, Stimulation-Only, Placebo) in a 1:1:1 ratio. After generating the sequence, the investigator allocated participants according to the predefined order to ensure transparency and unpredictability in group assignment.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究的原始数据由于涉及敏感信息,暂不公开共享。如有数据使用需求,在研究结束后,请联系研究负责人。联系方式如下:姓名:夏静;电子邮件:xj109664986@126.com

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data of this study are not publicly available due to the involvement of sensitive information. For data access requests, please contact the principal investigator after the trials completed. Contact details are as follows: Name: Xia Jing;Email: xj109664986@126.com

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(CRF) 设计与内容:CRF依据研究方案定制,涵盖基线数据(人口学信息、病史)、治疗记录(针灸/TMS参数)、评估结果(MoCA评分、P300潜伏期、MRS-NAA/Cr比值)、不良事件(AE/SAE)及中医证候信息。 填写流程:由研究者或指定护士在每次访视后24小时内完成填写,确保数据实时性。纸质CRF需双人核对(研究者+监查员),电子CRF通过ResMan系统录入。 存储与核对:纸质CRF存放于上锁档案室,电子CRF加密存储于云端服务器。数据管理员每周进行一次逻辑核查(如数值范围、缺失值),异常数据标记并反馈研究者修正。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form (CRF) Design & Content: The CRF is customized based on the study protocol, including baseline data (demographics, medical history), treatment records (acupuncture/TMS parameters), efficacy outcomes (MoCA scores, P300 latency, MRS-NAA/Cr ratio), adverse events (AEs/SAEs), and TCM syndrome information. Completion Process: Completed by investigators or designated nurses within 24 hours post-visit. Paper CRFs undergo dual verification (investigator + monitor), while electronic CRFs are entered via ResMan. Storage & Validation: Paper CRFs are stored in locked archives; electronic CRFs are encrypted and saved on cloud servers. Data managers perform weekly logic checks (e.g., value ranges, missing data) and flag discrepancies for investigator resolution.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above